Navigation Links
First Quantum Grant to fund stem cell repair of damage from stroke

"Each member of our team has made significant contributions to the advancement of their respective fields of research and will now be able to devote substantial efforts to integrating their work and developing methods of using neuro-vascular regeneration to help stroke victims," Hirschi said.

The project team members come from diverse and complementary areas of expertise in developmental neurobiology and vascular biology, stem cell biology, genetics, biomedical imaging, tissue engineering, and clinical cellular therapies. Spanning fields of science that include cell and molecular biology, animal models of disease, and hopefully human clinical trials, the "Neuro-Vascular Regeneration" project falls in line with the NIH roadmap for the development of multi-disciplinary and translational science.

The BCM team also includes project co-developer Mary Dickinson, assistant professor of molecular physiology and biophysics at BCM; Dr. Thomas Zwaka, assistant professor of molecular and cellular biology in the Center for Cell and Gene Therapy at BCM; and Malcolm Brenner, professor of medicine and pediatrics and director of the Center for Cell and Gene Therapy at BCM.

Robin Lovell-Badge, head of the division of developmental genetics at the National Institute for Medical Research in London, serves as co-principal investigator of the project. Other investigators in London include Jack Price and Mike Modo, both of the Centre for the Cellular Basis of Behaviour at the Institute of Psychiatry at King's College.


'"/>

Source:Rice University


Page: 1 2

Related biology news :

1. Timing is everything: First step in protein building revealed
2. Emory Eye Center Implants Its First Retinal Chips In Patients With Retinitis Pigmentosa
3. First atlas of key brain genes could speed research on cancer, neurological diseases
4. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
5. NYCs First Rapid HIV Drug-resistant AIDS Case Prompts Call to Step Up HIV Prevention
6. First real-time view of developing neurons reveals surprises, say Stanford researchers
7. Breast-Cancer Risk Linked to Exposure to Traffic Emissions at Menarche, First Birth
8. Mayo Clinic Researchers Create Obedient Virus; First Step To Use Measles Virus Against Cancer
9. First frozen egg baby born in Canada
10. Human Cells Filmed Instantly Messaging for First Time
11. First North American Encapsulated Islet Transplant without Long-term Immune Suppression into a Patient with Type 1 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: First Quantum Grant fund stem cell repair damage from stroke

(Date:5/29/2015)... Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ) ... Recognition Market by Solution, by Software, by Hardware, ... report to their offering. The ... become more efficient and cost effective. This has ... from the commercial sector. The development of 3D ...
(Date:5/28/2015)... , May 28, 2015 Industry ... of a new report titled "Markets for Self-Healing ... polymers, inorganic capsule and vascular systems, biomaterials, relevant ... grow to around $2.7 billion by 2020. ... n-tech,s extensive coverage of smart materials. Other recent n-tech ...
(Date:5/27/2015)... , May 27, 2015   ... medication safety systems and image documentation solutions ... of comprehensive, technologically-advanced automation solutions, is pleased ... integration. The Codonics® Safe Label System® (SLS), ... in conjunction with the Omnicell Anesthesia Workstation, ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
... is used to soothe every kind of pain, from simple ... is one of the most used nowadays. However, research carried ... University of Granada showed that taking paracetamol slows ... studies. Author of this work is Olga Garca Mart ...
... VIEW, Calif., Aug. 13 LaserCard,Corporation (Nasdaq: ... credentials,used in biometric identification, today announced the expansion ... Eastern government. A new centralized high-volume card ... optical memory and the eye-readable data of,this state-of-the-art ...
... deepens customer relationships, WALL, N.J., Aug. 15 ... leader in wireless public safety and,finger-based biometric identification ... quarter ended June 30, 2007. Total revenue ... 30, 2007 decreased 19% to $2.5 million from ...
Cached Biology News:Paracetamol, one of most used analgesics, could slow down bone growth 2LaserCard Corporation Announces Expansion of Middle East Project 2LaserCard Corporation Announces Expansion of Middle East Project 3BIO-key Reports Second Quarter 2007 Results 2BIO-key Reports Second Quarter 2007 Results 3BIO-key Reports Second Quarter 2007 Results 4BIO-key Reports Second Quarter 2007 Results 5
(Date:5/30/2015)... (PRWEB) May 30, 2015 The ... novel research for bile duct cancer, announced today ... Research Fellowship Program. , The Foundation ... scientists throughout the country to raise awareness about ... will support research that opens new pathways for ...
(Date:5/30/2015)... 2015 CTI BioPharma Corp. (CTI BioPharma) (NASDAQ ... BAX ) today announced data from PERSIST-1 – ... the treatment of myelofibrosis – in a late-breaking oral ... American Society of Clinical Oncology (ASCO), May 29-June 2, ... is an investigational oral multikinase inhibitor with specificity for ...
(Date:5/30/2015)... CHICAGO and RARITAN, N.J. ... the international, multi-center, open-label, two-part, single-arm Phase 2 ... – an investigational, human anti-CD38 monoclonal antibody – ... percent (95% CI, 20.8-38.9), as assessed by an ... multiple myeloma. The ORR was consistent among the ...
(Date:5/30/2015)... Texas , May 30, 2015  Caris ... from a study in which researchers identified biomarker ... metachronous paired glioma tumors, indicating changes in response ... observing 19 patients was a subset of a ... molecular heterogeneity of the cancer. These data utilizing ...
Breaking Biology Technology:The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 2The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 2Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 4Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 5Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 6Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 7Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 8Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 9Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 10Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 2Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 3Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 4Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 5Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 6Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 7Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 2Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 3Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 4
... ("Phosphagenics") (ASX: POH, AIM: PSG, OTCQX: PPGNY) today,announced ... that showed its,delivery technology, TPM, delivered leading pain-relief ... irritation of any kind., These results support ... a sustained release oxycodone patch for the management ...
... 17 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ; ... a,leading European pharmaceutical and medical devices company, ... Vasogen,s Celacade(TM) System,in Germany. Celacade, a first-in-class ... that specifically targets the destructive chronic,inflammation underlying ...
... SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ) today announced ... Board of Directors. Mr. Turner brings over 25 years ... serve on,the company,s audit committee., "We are delighted ... S.,Henney, Chairman of the Board of Directors of SGX. ...
Cached Biology Technology:Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results 2Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results 3Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure 2Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure 3Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure 4Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure 5SGX Pharmaceuticals Appoints Joseph L. Turner to Board of Directors 2SGX Pharmaceuticals Appoints Joseph L. Turner to Board of Directors 3
... it uses a deep-UV deuterium bulb, which provides ... a shutter (controlled via a TTL signal or ... DH-2000 Deuterium Tungsten Halogen Light Source combines the ... sources in a single optical path. The combined-spectrum ...
... These handy dispensers save space ... hats, and other garb. They are ... small parts used in labs, processing ... static charges and the particles they ...
... production by luciferase-cDNA transfected cell lines has ... the development of reporter gene assays in ... indicator for the transcription of other genes. ... due to advantages such as high sensitivity ...
... Thermostable dUTPase The ... of high-fidelity PCR (using proofreading DNA ... present in PCR reactions and dNTP ... in a proofreading DNA polymerase reaction ...
Biology Products: